Holocene Advisors’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-2,117,228
Closed -$6.61M 790
2023
Q3
$6.61M Hold
2,117,228
0.03% 339
2023
Q2
$9.72M Hold
2,117,228
0.04% 257
2023
Q1
$10.5M Sell
2,117,228
-620,382
-23% -$3.05M 0.05% 235
2022
Q4
$14.9M Sell
2,737,610
-304,350
-10% -$1.87M 0.09% 208
2022
Q3
$19.8M Hold
3,041,960
0.13% 182
2022
Q2
$14.4M Buy
3,041,960
+44,434
+1% +$219K 0.09% 199
2022
Q1
$21M Buy
2,997,526
+22,764
+0.8% +$155K 0.11% 185
2021
Q4
$30.3M Buy
2,974,762
+542,040
+22% +$5.82M 0.16% 165
2021
Q3
$29.7M Buy
+2,432,722
New +$36.7M 0.16% 169

Other funds holding MXCT

Holocene Advisors's MXCT Position: Q4 2023 in Review

Holocene Advisors sold out of MaxCyte (MXCT) in Q4 2023, closing a stake of 2,117,228 shares — an estimated $6.61M sold.

Holocene Advisors first reported a position in MXCT in Q3 2021 and held it in 9 quarters. The position peaked at $30.3M in Q4 2021. 120 funds tracked by Wall St. Rank hold MXCT as of Q4 2023.

  • Holocene Advisors reported no remaining MaxCyte position as of Q4 2023 after selling out during the quarter.
  • Holocene Advisors sold 2,117,228 MaxCyte shares in Q4 2023, an estimated $6.61M.
  • Holocene Advisors first reported a position in MaxCyte in Q3 2021 and held it in 9 quarters.
  • Holocene Advisors's MaxCyte position peaked at $30.3M in Q4 2021.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q4 2023.

Based on Holocene Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.